Drug Trial Radar · NCT05912075
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Dec 19, 2023
Primary completion
Jan 1, 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Compare two arms: * Chemotherapy followed by tolinapant (ASTX660) in combination with Long-Course Radio Chemotherapy (LCRT), and * Tolinapant (ASTX660) in combination with Short-Course Radiotherapy (SCRT) followed by chemotherapy For each patient, the treatment arm will be allocated on the following basis: patients will be allocated to the chemotherapy followed by LCRT arm unless they present at least one of the following criteria: contraindication to receive mFOLFIRINOX (including intolerance to irinotecan and UGT1A1\*28 polymorphism), age \> 75, general condition incompatible with the radiotherapy schedule of LCRT. In such case, patients will be allocated to the SCRT arm. Tolinapant (ASTX660) will be administered orally once a day for 7 consecutive days every other week during 10 weeks (One week On / One week Off during 10 weeks). Both treatment arms will have a dose escalation part to determine the MTD and/or RP2D, followed by an expansion part where up to 21 subjects will be dosed at the RP2D. Both arms will enroll simultaneously.
Conditions
- Locally-advanced Rectal Cancer
Interventions
mFOLFIRINOXDrug
prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
Pelvic radiotherapy LCRTRadiation
50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
CapecitabineDrug
800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
TOLINAPANT (ASTX660)Drug
starting from 14 days before the first dose of radiotherapy, for 10 weeks.
Pelvic radiotherapy SCRTRadiation
total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
FOLFOX4Drug
given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
CAPOXDrug
every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLTs)Time frame: during the 10 weeks of tolinapant (ASTX660) treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centre Léon Bérard
Lyon, Rhöne, France · Not yet recruiting
Gustave Roussy
Villejuif, Val De Marne, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.